Authors: Rybczynska, M Liu, R Lu, P Sharom, FJ Steinfels, E Di Pietro, A Spitaler, M Grunicke, H Hofmann, J

Citation: M. Rybczynska et al., MDR1 causes resistance to the antitumour drug miltefosine, BR J CANC, 84(10), 2001, pp. 1405-1411

Authors: Rybczynska, M Spitaler, M Knebel, NG Boeck, G Grunicke, H Hofmann, J

Citation: M. Rybczynska et al., Effects of miltefosine on various biochemical parameters in a panel of tumor cell lines with different sensitivities, BIOCH PHARM, 62(6), 2001, pp. 765-772

Authors: Spitaler, M Villunger, A Grunicke, H Uberall, F

Citation: M. Spitaler et al., Unique structural and functional properties of the ATP-binding domain of atypical protein kinase C-iota, J BIOL CHEM, 275(43), 2000, pp. 33289-33296

Authors: Spitaler, M Wiesenhofer, B Biedermann, V Seppi, T Zimmermann, J Grunicke, H Hofmann, J

Citation: M. Spitaler et al., The involvement of protein kinase C isoenzymes alpha, epsilon and zeta in the sensitivity to antitumor treatment and apoptosis induction, ANTICANC R, 19(5B), 1999, pp. 3969-3976

Authors: Lindner, H Sarg, B Grunicke, H Helliger, W

Citation: H. Lindner et al., Age-dependent deamidation of H1 degrees histones in chromatin of mammaliantissues, J CANC RES, 125(3-4), 1999, pp. 182-186

Authors: Putz, T Culig, Z Eder, IE Nessler-Menardi, C Bartsch, G Grunicke, H Uberall, F Klocker, H

Citation: T. Putz et al., Epidermal growth factor (EGF) receptor blockade inhibits the action of EGF, insulin-like growth factor I, and a protein kinase A activator on the mitogen-activated protein kinase pathway in prostate cancer cell lines, CANCER RES, 59(1), 1999, pp. 227-233